EPISODE · Sep 3, 2026 · 39 MIN
GLP-1s, Anhedonia, and the Dopamine Trade-Off with Dr. Robin Berzin
from Commune with Jeff Krasno · host Commune
A low dose of tirzepatide, taken purely to move the needle on cholesterol, turned out to move a lot more than that. In this episode, Jeff sits down again with Dr. Robin Berzin, founder of Parsley Health, to go through his bloodwork and an unexpected side effect: a blunting of desire that shows up in his coffee, his cocktails, and his ambition. Why losing your appetite for food can also mean losing it for coffee, alcohol, and sex What the dopamine and serotonin circuitry are actually doing on a GLP-1 The line between healthy desire and maladaptive craving, and where these drugs land on it Why some people feel liberated when "food noise" disappears, and others feel flattened What Jeff's ApoB and LDL numbers say about who these drugs actually help This episode is for anyone on a GLP-1 or weighing one, and anyone curious what these drugs are doing beyond the scale. This episode was made possible by: LMNT: Get a free 8-count Sample Pack of LMNT’s most popular drink mix flavors with any purchase at drinklmnt.com/commune. Vivobarefoot: Try Vivobarefoot risk-free with a 100-day return guarantee, and get 20% off your order at vivobarefoot.com/commune. Stemregen: Get 20% off your first order at stemregen.co/commune with the code COMMUNEPOD LMNT: Get a free 8-count Sample Pack of LMNT’s most popular drink mix flavors with any purchase at drinklmnt.com/commune. CocoaVia: Use code COMMUNE2026 for 25% off at CocoaVia.com
Embed this episode
NOW PLAYING
GLP-1s, Anhedonia, and the Dopamine Trade-Off with Dr. Robin Berzin
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.